The FDA recently (in August 2019) approved transcatheter aortic valve replacement (TAVR) for lower surgical risk patients. This means that younger, healthier patients will now have the opportunity to benefit from the quicker recovery of this less invasive therapy for aortic stenosis. The heart team at Piedmont’s Marcus Heart Valve Center discusses the impact on patients, practice, and Piedmont’s experience as a high-volume, comprehensive valve center and a national leader in transcatheter therapies.

Find out more at piedmont.org/TAVR